Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors

Valentina Gandin, Cecilia Ceresa, Giovanni Esposito, Stefano Indraccolo, Marina Porchia, Francesco Tisato, Carlo Santini, Maura Pellei, Cristina Marzano

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

[Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy. HydroCuP potently inhibited the growth of human cancer cells derived from solid tumors by inducing endoplasmatic reticulum (ER) stress thus leading to cell death through paraptosis with a preferential efficacy against cancer rather than non-cancer cells. Aim of the present study was to assess the therapeutic potential of HydroCuP in vivo, in syngenic and xenograft murine models of solid tumors by triggering the Unfolded Protein Response (UPR) pathway. With respect to platinum drugs, HydroCuP induced a markedly higher reduction of tumor growth associated with minimal animal toxicity. In human colorectal cancer xenografts, chemotherapy with HydroCuP was extremely effective in both oxaliplatin-sensitive and resistant models. The favorable in vivo tolerability of HydroCuP was also correlated to an encouraging biodistribution profile. Additionally, no signs of drug-related neurotoxicity and nephrotoxicity were observed. Altogether, these results demonstrate that HydroCuP appears worth of further investigation to evaluate its therapeutic activity towards a broad spectrum of solid malignancies.

Original languageEnglish
Article number13936
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Neoplasms
oxaliplatin
Platinum
Heterografts
Therapeutics
Unfolded Protein Response
Drug Therapy
Reticulum
Growth
Pharmaceutical Preparations
Copper
Colorectal Neoplasms
Cell Death
tetrakis(tris(hydroxymethyl)phosphine)copper(I)

ASJC Scopus subject areas

  • General

Cite this

Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. / Gandin, Valentina; Ceresa, Cecilia; Esposito, Giovanni; Indraccolo, Stefano; Porchia, Marina; Tisato, Francesco; Santini, Carlo; Pellei, Maura; Marzano, Cristina.

In: Scientific Reports, Vol. 7, No. 1, 13936, 01.12.2017.

Research output: Contribution to journalArticle

Gandin, V, Ceresa, C, Esposito, G, Indraccolo, S, Porchia, M, Tisato, F, Santini, C, Pellei, M & Marzano, C 2017, 'Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors', Scientific Reports, vol. 7, no. 1, 13936. https://doi.org/10.1038/s41598-017-13698-1
Gandin, Valentina ; Ceresa, Cecilia ; Esposito, Giovanni ; Indraccolo, Stefano ; Porchia, Marina ; Tisato, Francesco ; Santini, Carlo ; Pellei, Maura ; Marzano, Cristina. / Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{4b544fe640544a06a52a47b83325706f,
title = "Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors",
abstract = "[Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy. HydroCuP potently inhibited the growth of human cancer cells derived from solid tumors by inducing endoplasmatic reticulum (ER) stress thus leading to cell death through paraptosis with a preferential efficacy against cancer rather than non-cancer cells. Aim of the present study was to assess the therapeutic potential of HydroCuP in vivo, in syngenic and xenograft murine models of solid tumors by triggering the Unfolded Protein Response (UPR) pathway. With respect to platinum drugs, HydroCuP induced a markedly higher reduction of tumor growth associated with minimal animal toxicity. In human colorectal cancer xenografts, chemotherapy with HydroCuP was extremely effective in both oxaliplatin-sensitive and resistant models. The favorable in vivo tolerability of HydroCuP was also correlated to an encouraging biodistribution profile. Additionally, no signs of drug-related neurotoxicity and nephrotoxicity were observed. Altogether, these results demonstrate that HydroCuP appears worth of further investigation to evaluate its therapeutic activity towards a broad spectrum of solid malignancies.",
author = "Valentina Gandin and Cecilia Ceresa and Giovanni Esposito and Stefano Indraccolo and Marina Porchia and Francesco Tisato and Carlo Santini and Maura Pellei and Cristina Marzano",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-13698-1",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors

AU - Gandin, Valentina

AU - Ceresa, Cecilia

AU - Esposito, Giovanni

AU - Indraccolo, Stefano

AU - Porchia, Marina

AU - Tisato, Francesco

AU - Santini, Carlo

AU - Pellei, Maura

AU - Marzano, Cristina

PY - 2017/12/1

Y1 - 2017/12/1

N2 - [Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy. HydroCuP potently inhibited the growth of human cancer cells derived from solid tumors by inducing endoplasmatic reticulum (ER) stress thus leading to cell death through paraptosis with a preferential efficacy against cancer rather than non-cancer cells. Aim of the present study was to assess the therapeutic potential of HydroCuP in vivo, in syngenic and xenograft murine models of solid tumors by triggering the Unfolded Protein Response (UPR) pathway. With respect to platinum drugs, HydroCuP induced a markedly higher reduction of tumor growth associated with minimal animal toxicity. In human colorectal cancer xenografts, chemotherapy with HydroCuP was extremely effective in both oxaliplatin-sensitive and resistant models. The favorable in vivo tolerability of HydroCuP was also correlated to an encouraging biodistribution profile. Additionally, no signs of drug-related neurotoxicity and nephrotoxicity were observed. Altogether, these results demonstrate that HydroCuP appears worth of further investigation to evaluate its therapeutic activity towards a broad spectrum of solid malignancies.

AB - [Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy. HydroCuP potently inhibited the growth of human cancer cells derived from solid tumors by inducing endoplasmatic reticulum (ER) stress thus leading to cell death through paraptosis with a preferential efficacy against cancer rather than non-cancer cells. Aim of the present study was to assess the therapeutic potential of HydroCuP in vivo, in syngenic and xenograft murine models of solid tumors by triggering the Unfolded Protein Response (UPR) pathway. With respect to platinum drugs, HydroCuP induced a markedly higher reduction of tumor growth associated with minimal animal toxicity. In human colorectal cancer xenografts, chemotherapy with HydroCuP was extremely effective in both oxaliplatin-sensitive and resistant models. The favorable in vivo tolerability of HydroCuP was also correlated to an encouraging biodistribution profile. Additionally, no signs of drug-related neurotoxicity and nephrotoxicity were observed. Altogether, these results demonstrate that HydroCuP appears worth of further investigation to evaluate its therapeutic activity towards a broad spectrum of solid malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85032218214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032218214&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-13698-1

DO - 10.1038/s41598-017-13698-1

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 13936

ER -